C. Kreft-Jaïs

1.2k total citations
38 papers, 774 citations indexed

About

C. Kreft-Jaïs is a scholar working on Toxicology, Pharmacology and Immunology. According to data from OpenAlex, C. Kreft-Jaïs has authored 38 papers receiving a total of 774 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Toxicology, 10 papers in Pharmacology and 6 papers in Immunology. Recurrent topics in C. Kreft-Jaïs's work include Pharmacovigilance and Adverse Drug Reactions (16 papers), Drug-Induced Adverse Reactions (8 papers) and Biosimilars and Bioanalytical Methods (5 papers). C. Kreft-Jaïs is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (16 papers), Drug-Induced Adverse Reactions (8 papers) and Biosimilars and Bioanalytical Methods (5 papers). C. Kreft-Jaïs collaborates with scholars based in France, Spain and Switzerland. C. Kreft-Jaïs's co-authors include Pierre‐François Plouin, Françoise Haramburu, Xavier Jeunemaı̂tre, Joël Ménard, Gilles Châtellier, Anne Charru, Pierre Corvol, C Devriès, Bernard Bégaud and C. Noblet and has published in prestigious journals such as The American Journal of Cardiology, Statistics in Medicine and Transplantation.

In The Last Decade

C. Kreft-Jaïs

38 papers receiving 751 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Kreft-Jaïs France 14 249 211 166 138 104 38 774
Annamaria Mascolo Italy 24 203 0.8× 231 1.1× 160 1.0× 173 1.3× 270 2.6× 64 1.2k
Carmen Ferrajolo Italy 24 266 1.1× 139 0.7× 152 0.9× 201 1.5× 89 0.9× 56 1.4k
Liberata Sportiello Italy 24 241 1.0× 363 1.7× 254 1.5× 251 1.8× 149 1.4× 76 1.6k
Salvatore Crisafulli Italy 15 153 0.6× 118 0.6× 83 0.5× 74 0.5× 75 0.7× 38 872
B.‐E. Wiholm Sweden 23 195 0.8× 371 1.8× 217 1.3× 220 1.6× 104 1.0× 35 1.7k
Lynette Swartz United States 6 248 1.0× 95 0.5× 80 0.5× 56 0.4× 262 2.5× 6 990
Hitomi Teramachi Japan 16 294 1.2× 68 0.3× 161 1.0× 104 0.8× 63 0.6× 174 1.2k
Luisa Ibáñez Spain 21 122 0.5× 68 0.3× 248 1.5× 152 1.1× 171 1.6× 52 1.4k
Tomomi Kimura Japan 21 111 0.4× 94 0.4× 141 0.8× 120 0.9× 199 1.9× 91 1.5k
Mio Sakuma Japan 16 102 0.4× 122 0.6× 83 0.5× 131 0.9× 181 1.7× 60 889

Countries citing papers authored by C. Kreft-Jaïs

Since Specialization
Citations

This map shows the geographic impact of C. Kreft-Jaïs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Kreft-Jaïs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Kreft-Jaïs more than expected).

Fields of papers citing papers by C. Kreft-Jaïs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Kreft-Jaïs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Kreft-Jaïs. The network helps show where C. Kreft-Jaïs may publish in the future.

Co-authorship network of co-authors of C. Kreft-Jaïs

This figure shows the co-authorship network connecting the top 25 collaborators of C. Kreft-Jaïs. A scholar is included among the top collaborators of C. Kreft-Jaïs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Kreft-Jaïs. C. Kreft-Jaïs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Buyck, Jean-François, et al.. (2016). Attitudes et pratiques des médecins généralistes dans le cadre du suivi de la grossesse. 1 indexed citations
2.
Kreft-Jaïs, C., et al.. (2014). Effects of Alcoholic Beverage Control Policies and Contextual Factors on Alcohol Consumption and its Related Harms in France From 1960 to 2000. Substance Use & Misuse. 49(12). 1633–1645. 9 indexed citations
3.
Arwidson, Pierre & C. Kreft-Jaïs. (2013). Le nécessaire apport de la science à la prévention. Global Health Promotion. 20(2_suppl). 5–7. 1 indexed citations
4.
Laroche, Marie‐Laure, Marie‐Christine Pérault‐Pochat, Isabelle Ingrand, et al.. (2013). Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross‐sectional study. Pharmacoepidemiology and Drug Safety. 22(9). 952–960. 39 indexed citations
5.
Durrieu, Geneviève, Aurore Palmaro, Laure Pourcel, et al.. (2012). First French Experience of ADR Reporting by Patients After a Mass Immunization Campaign with Influenza A (H1N1) Pandemic Vaccines. Drug Safety. 35(10). 845–854. 2 indexed citations
6.
Lebrun‐Vignes, Bénédicte, C. Kreft-Jaïs, A Castot, & O. Chosidow. (2012). Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. British Journal of Dermatology. 166(6). 1333–1341. 36 indexed citations
7.
Durrieu, Geneviève, Céline Caillet, Isabelle Lacroix, et al.. (2011). Campagne nationale de vaccination contre la grippe A (H1N1)v : suivi national de pharmacovigilance. Therapies. 66(6). 527–540. 4 indexed citations
8.
Autret‐Leca, E., et al.. (2010). Isotretinoin Exposure during Pregnancy. Drug Safety. 33(8). 659–665. 20 indexed citations
9.
Peyrière, Hélène, et al.. (2009). Antipsychotics‐induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiology and Drug Safety. 18(10). 948–955. 41 indexed citations
10.
Lamarque, Véronique, Louis Merle, Haleh Bagheri, et al.. (2008). Génériques et modalités de substituabilité : propositions de méthodes pour évaluer l’équivalence, la traçabilité et le relevé de Pharmacovigilance. Therapies. 63(4). 301–309. 3 indexed citations
11.
Louët, Hervé Le, Elisabeth Loupi, Didier Guillemot, et al.. (2007). Which Pharmacovigilance for Vaccines?. Therapies. 62(3). 245–247. 3 indexed citations
12.
Louët, Hervé Le, Elisabeth Loupi, Didier Guillemot, et al.. (2007). Quelle pharmacovigilance pour les vaccins ?. Therapies. 62(3). 241–244. 2 indexed citations
13.
Jacqz-Aigrain, Évelyne, Véronique Lamarque, E. Autret‐Leca, et al.. (2006). Méthodes de surveillance et de gestion des risques des médicaments pour la future mère, l’embryon, le fœtus et le nouveau-né. Therapies. 61(4). 287–295. 2 indexed citations
14.
Clinard, François, Catherine Sgro, Marc Bardou, et al.. (2004). Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. European Journal of Clinical Pharmacology. 60(4). 279–83. 18 indexed citations
15.
Moore, Nicholas M., C. Kreft-Jaïs, Françoise Haramburu, et al.. (1997). Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non‐case study in the French pharmacovigilance system database. British Journal of Clinical Pharmacology. 44(5). 513–518. 108 indexed citations
16.
Moore, Nicholas, C. Noblet, C. Kreft-Jaïs, et al.. (1996). [French pharmacovigilance database system: examples of utilisation].. PubMed. 50(6). 557–62. 52 indexed citations
17.
Billaud, Eliane M., R. Guillemain, Nicolas Fortineau, et al.. (1990). Interaction Between Roxithromycin and Cyclosporin in Heart Transplant Patients. Clinical Pharmacokinetics. 19(6). 499–502. 21 indexed citations
18.
Baumelou, A, C Bénichou, A Castot, et al.. (1989). [Drug-induced renal insufficiency. Results of consensus meetings].. PubMed. 10(3). 157–61. 9 indexed citations
19.
Jeunemaı̂tre, Xavier, C. Kreft-Jaïs, Gilles Châtellier, et al.. (1988). Long-term experience of spironolactone in essential hypertension.. PubMed. 26. S14–7. 13 indexed citations
20.
Jeunemaı̂tre, Xavier, Gilles Châtellier, C. Kreft-Jaïs, et al.. (1987). Efficacy and tolerance of spironolactone in essential hypertension. The American Journal of Cardiology. 60(10). 820–825. 197 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annamaria Mascolo Breakdown of academic impact, for papers by Carmen Ferrajolo Breakdown of academic impact, for papers by Liberata Sportiello Breakdown of academic impact, for papers by Salvatore Crisafulli Breakdown of academic impact, for papers by B.‐E. Wiholm Breakdown of academic impact, for papers by Lynette Swartz Breakdown of academic impact, for papers by Hitomi Teramachi Breakdown of academic impact, for papers by Luisa Ibáñez Breakdown of academic impact, for papers by Tomomi Kimura Breakdown of academic impact, for papers by Mio Sakuma
Rankless by CCL
2026